Anavex Life Sciences Corp (AVXL)

[Investor2014]

You will have to backup that assertion with a factual reference.

Even if it had in Europe the assignment issue between Anavex and the inventors appears unresolved. It’s a critical factor in Anavex’s ability to enforce its patents internationally.

From SEC Filings:
• 2014 Form 10-K: Anavex disclosed it was “awaiting formal patent documents from a co-inventor as to two applications, and seeking one assignment from the same co-inventor to an application assigned to Anavex by another co-inventor.” Essentially, Anavex had not yet received the full legal rights from one of the inventors, which could impact their ability to obtain and enforce those patents.
• Earlier filings (2013) similarly noted that Anavex was waiting on a contractually obligated patent assignment from one of the two named inventors for one of their patent applications.

These statements indicate that Anavex did not have uncontested ownership of certain patent applications—unless the assignment was completed.

Why It Matters in Europe (and Elsewhere)

Patent authorities in many jurisdictions—including the European Patent Office (EPO)—require clear proof that the applicant has the legal right to file the patent (i.e., that assignments have been properly executed). If assignment documents remain outstanding, the application may be refused or suffer enforcement challenges—even if the patent is granted.

Therefore, if this assignment dispute wasn’t fully resolved, Anavex’s European patents (or PCT filings/designated national filings) could be in jeopardy—and enforcement would be impaired.